Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Fletcher

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Microorganisms|May 28, 2022
Correction: Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). <i>Microorganisms</i> 2022, <i>10</i>, 127Christian Theilacker, Mark A Fletcher, Luis Jodar, et al.
Microorganisms|January 21, 2022
PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)Christian Theilacker, Mark A Fletcher, Luis Jodar, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 2, 2025
Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022Mark A Fletcher, Omar Okasha, Marc Baay, et al.
Vaccine|October 20, 2006
Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)Daniel J Isaacman, Mark A Fletcher, Bernard Fritzell, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 9, 2019
<i>Streptococcus pneumoniae</i> as a Cause of Community-Acquired Pneumonia in Indian Adolescents and Adults: A Systematic Review and Meta-AnalysisCanna J Ghia, Raja Dhar, Parvaiz A Koul, et al.
The Lancet. Infectious Diseases|January 30, 2021
Comparing the effect of PCV10 and PCV13 paediatric vaccination programmesChristian Theilacker, Mark A Fletcher, Julia R Spinardi, et al.
Psychophysiology|March 22, 2017
Shedding light on gray(ing) areas: Connectivity and task switching dynamics in agingPauline L Baniqued, Kathy A Low, Mark A Fletcher, et al.
Vaccine|May 28, 2019
Letter to streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010-2015: A systematic review and a time series analysisRodrigo Sini de Almeida, Jorge LaRotta, Mark A Fletcher, et al.
Infectious Diseases and Therapy|December 13, 2018
Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or AlgeriaSarah J Pugh, Mark A Fletcher, Apostolos Charos, et al.
Anaerobe|February 9, 2024
The burden of Clostridioides difficile infections in South-East Asia and the Western Pacific: A narrative reviewFrederick J Angulo, Canna Ghia, Mark A Fletcher, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Microorganisms|May 28, 2022
Correction: Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). <i>Microorganisms</i> 2022, <i>10</i>, 127Christian Theilacker, Mark A Fletcher, Luis Jodar, et al.
Microorganisms|January 21, 2022
PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)Christian Theilacker, Mark A Fletcher, Luis Jodar, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 2, 2025
Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022Mark A Fletcher, Omar Okasha, Marc Baay, et al.
Vaccine|October 20, 2006
Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)Daniel J Isaacman, Mark A Fletcher, Bernard Fritzell, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 9, 2019
<i>Streptococcus pneumoniae</i> as a Cause of Community-Acquired Pneumonia in Indian Adolescents and Adults: A Systematic Review and Meta-AnalysisCanna J Ghia, Raja Dhar, Parvaiz A Koul, et al.
The Lancet. Infectious Diseases|January 30, 2021
Comparing the effect of PCV10 and PCV13 paediatric vaccination programmesChristian Theilacker, Mark A Fletcher, Julia R Spinardi, et al.
Psychophysiology|March 22, 2017
Shedding light on gray(ing) areas: Connectivity and task switching dynamics in agingPauline L Baniqued, Kathy A Low, Mark A Fletcher, et al.
Vaccine|May 28, 2019
Letter to streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010-2015: A systematic review and a time series analysisRodrigo Sini de Almeida, Jorge LaRotta, Mark A Fletcher, et al.
Infectious Diseases and Therapy|December 13, 2018
Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or AlgeriaSarah J Pugh, Mark A Fletcher, Apostolos Charos, et al.
Anaerobe|February 9, 2024
The burden of Clostridioides difficile infections in South-East Asia and the Western Pacific: A narrative reviewFrederick J Angulo, Canna Ghia, Mark A Fletcher, et al.
Pageof 6